Biocon: Company Gets EIR With VAI Status From U.S. FDA For New Jersey Facility

 18 Dec 2025 05:51 PM

Biocon: Company Gets EIR With VAI Status From U.S. FDA For New Jersey Facility

Biocon: Company Launches Liraglutide, A Glucagon-Like Peptide-1, In The Netherland

 15 Dec 2025 08:54 AM

Biocon: Company Launches Liraglutide, A Glucagon-Like Peptide-1, In The Netherland

Biocon: Company Introduces Liraglutide, A Glucagon-Like Peptide-1, In The Netherlands, Marketing It As Diavorin® And Vobexoryn®; This Marks Their First EU Launch Under Their Own Brand After MEB Approval

 15 Dec 2025 08:55 AM

Biocon: Company Introduces Liraglutide, A Glucagon-Like Peptide-1, In The Netherlands, Marketing It As Diavorin® And Vobexoryn®; This Marks Their First EU Launch Under Their Own Brand After MEB Approval

BIOCON: CO. SIGNS SETTLEMENT AND LICENSE AGREEMENT TO COMMERCIALIZE BIOSIMILAR AFLIBERCEPT WORLDWIDE; AGREEMENT CLEARS PATH FOR LAUNCH IN UK JANUARY 2026 AND OTHER COUNTRIES BY MARCH 2026.

 13 Dec 2025 01:46 PM

BIOCON: CO. SIGNS SETTLEMENT AND LICENSE AGREEMENT TO COMMERCIALIZE BIOSIMILAR AFLIBERCEPT WORLDWIDE; AGREEMENT CLEARS PATH FOR LAUNCH IN UK JANUARY 2026 AND OTHER COUNTRIES BY MARCH 2026.

Biocon: Avendus Spark on Biocon maintains 'Add' with Price Target of Rs 435

 08 Dec 2025 09:00 AM

Biocon: Avendus Spark on Biocon maintains 'Add' with Price Target of Rs 435

Biocon: Goldman Sachs on Biocon Neutral, Price Target Rs 375

 08 Dec 2025 09:00 AM

Biocon: Goldman Sachs on Biocon Neutral, Price Target Rs 375

Biocon: BOFA SEC on Biocon Buy, Price Target Rs 455

 08 Dec 2025 09:02 AM

Biocon: BOFA SEC on Biocon Buy, Price Target Rs 455

Biocon: Board Greenlights Fundraising of Up to ₹4,500 Crore Through Various Securities for Cash to Mylan

 06 Dec 2025 03:04 PM

Biocon: Board Greenlights Fundraising of Up to ₹4,500 Crore Through Various Securities for Cash to Mylan

Biocon: Company Gets Tentative FDA Nod For Carbidope And Levodopa Extended-Release Capsules For Parkinson's Disease

 05 Dec 2025 06:21 PM

Biocon: Company Gets Tentative FDA Nod For Carbidope And Levodopa Extended-Release Capsules For Parkinson's Disease

Biocon: Company To Explore Raising Funds Through Commercial Paper Or Issuing Shares on Dec 6

 04 Dec 2025 08:35 AM

Biocon: Company To Explore Raising Funds Through Commercial Paper Or Issuing Shares on Dec 6

Biocon: Plans To Invest In Biocon Biologics By Purchasing Securities From Shareholders On December 6

 04 Dec 2025 08:35 AM

Biocon: Plans To Invest In Biocon Biologics By Purchasing Securities From Shareholders On December 6

Biocon: Company Confirms Launch Date For Denosumab Biosimilars In Europe And Worldwide; Agreement With Amgen Allows For Sales; Vevzuo® And Evfaxy® Set To Release On December 2, 2025

 02 Dec 2025 09:07 AM

Biocon: Company Confirms Launch Date For Denosumab Biosimilars In Europe And Worldwide; Agreement With Amgen Allows For Sales; Vevzuo® And Evfaxy® Set To Release On December 2, 2025

Biocon: Gets USFDA Green Light For Tofacitinib Extended-Release Tablets; Final Approval For 11mg Strength And Tentative Approval For 22mg Strength; Used For Rheumatoid Arthritis And Other Conditions.

 19 Nov 2025 09:09 AM

Biocon: Gets USFDA Green Light For Tofacitinib Extended-Release Tablets; Final Approval For 11mg Strength And Tentative Approval For 22mg Strength; Used For Rheumatoid Arthritis And Other Conditions.

Biocon: Co Managing Director States No Board Action Taken Yet on Biocon Biologics Merger.

 13 Nov 2025 10:22 AM

Biocon: Co Managing Director States No Board Action Taken Yet on Biocon Biologics Merger.

Biocon: Co Management Anticipates Margins of Around 40% from October to March, -Concall Updates

 12 Nov 2025 09:34 AM

Biocon: Co Management Anticipates Margins of Around 40% from October to March, -Concall Updates

BioCon: To Acquire CCDS Of BioCon Biologics For 3 Billion Rupees 💰📈

 11 Nov 2025 08:39 PM

BioCon: To Acquire CCDS Of BioCon Biologics For 3 Billion Rupees 💰📈

BIOCON: Q2 CONS NET PROFIT 1.3B RUPEES VS 271M (YOY); EST 750M || Q2 REVENUE 45.95B RUPEES VS 35.9B (YOY); EST 41.5B

 11 Nov 2025 08:32 PM

BIOCON: Q2 CONS NET PROFIT 1.3B RUPEES VS 271M (YOY); EST 750M || Q2 REVENUE 45.95B RUPEES VS 35.9B (YOY); EST 41.5B

BIOCON: Q2 EBITDA 8.35B RUPEES VS 6.85B (YOY); EST 8.40B || Q2 EBITDA MARGIN 19.45% VS 19.09% (YOY); EST 21%

 11 Nov 2025 08:34 PM

BIOCON: Q2 EBITDA 8.35B RUPEES VS 6.85B (YOY); EST 8.40B || Q2 EBITDA MARGIN 19.45% VS 19.09% (YOY); EST 21%

BIOCON: Q2 CONS NET PROFIT 1.3B RUPEES VS 271M (YOY); EST 750M || Q2 REVENUE 42.95B RUPEES VS 35.9B (YOY); EST 41.5B (CORRECTION IN REVENUE)

 11 Nov 2025 08:34 PM

BIOCON: Q2 CONS NET PROFIT 1.3B RUPEES VS 271M (YOY); EST 750M || Q2 REVENUE 42.95B RUPEES VS 35.9B (YOY); EST 41.5B (CORRECTION IN REVENUE)